Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

Early Phase 1TerminatedNCT01147601

Oregon Health and Science University6 enrolled

Overview

The purpose of this study is to learn about a new potential use for topical timolol 0.5% aqueous solution that may help treat small uncomplicated infantile hemangiomas. This study would examine whether topical timolol could be a potential therapy.

At the first visit, subjects will fill out a questionnaire that asks about the child's history and the hemangioma. Photographs and measurements will be taken at this and each subsequent visit. At the first visit, subjects will have a physical exam, including vital signs, height and weight. An EKG will also be done. Study drug will be dispensed and instructions given. Half of the subjects will receive a placebo. This is a blinded randomized study. Follow-up visits will be weekly for the first two weeks (three visits total including the first visit), then monthly until the study is over. Photographs and measurements will again be taken at each visit. Subjects will be asked to evaluate the size and the color of the hemangioma against the first photographs and fill out forms regarding any changes in behavior and asked about any side effects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hemangioma Infant

Interventions

topical 0.5% TimololDRUG

topical 0.5% Timolol aqueous solution, 2-3 drops to cover the hemangioma, twice daily

Control (placebo) groupDRUG

Control (placebo) group

Eligibility

Sex: ALLMin age: 1 MonthMax age: 8 Months

Medical Language ↔ Plain English

Inclusion Criteria: Infants 1 month to 8 months of age with infantile hemangioma (IH) that are 3 cm or less on the scalp, trunk, or extremities. Exclusion Criteria: 1. Subjects with facial, genital, perianal, hand, finger, feet, or toe IH 2. Subjects with PHACES (plaque-like hemangioma on the face awaiting imaging) syndrome (proven) or suspected PHACES . 3. Subjects with IH measuring more than 3cm in size or ulcerated. 4. Children with a history of hypersensitivity to beta blockers. 5. Children with a personal history of asthma. 6. Children with known renal impairment. 7. Children with known cardiac conditions that may predispose to heart block 8. Personal history of hypoglycemia 9. Children on medications that may interact with beta blockers

Locations (1)

Oregon Health & Science University

Portland, Oregon, United States

Outcomes

Primary Outcomes

Proportion of Subjects in Treatment Group Compared to Placebo Group With at Least 75% Improvement in the Extent of the Hemangioma as Compared to Baseline Photos.

This will be generated by asking each of the assessors to score the improvement using a visual analog scale (VAS) assessing the decrease in size of hemangioma by comparing photographs at different times of treatment. The assessors will score this improvement into one of the following categories: 0-24%, 25-49%, 50-74%, \>75%.

Time frame: at 6 months

Secondary Outcomes

Compare Treatment Group to Control Group Improvement Assessments

1. The proportion of subjects in the treatment group as compared to the placebo control group with at least 50% improvement in the extent of the hemangioma. 2. The difference between the extent/size of the hemangioma as an outcome measure versus color changes. 3. Frequency of adverse events (e.g. hypotension, behavioral changes, etc.), collected by the investigator and reported by the parents.

Time frame: at 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.